Viridian Therapeutics Inc - Asset Resilience Ratio
Viridian Therapeutics Inc (VRDN) has an Asset Resilience Ratio of 73.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Viridian Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Viridian Therapeutics Inc's Asset Resilience Ratio has changed over time. See Viridian Therapeutics Inc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Viridian Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VRDN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $662.27 Million | 73.63% |
| Total Liquid Assets | $662.27 Million | 73.63% |
Asset Resilience Insights
- Very High Liquidity: Viridian Therapeutics Inc maintains exceptional liquid asset reserves at 73.63% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Viridian Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Viridian Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Viridian Therapeutics Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Viridian Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.63% | $662.27 Million | $899.42 Million | -9.61pp |
| 2024-12-31 | 83.24% | $617.99 Million | $742.40 Million | +6.87pp |
| 2023-12-31 | 76.37% | $374.54 Million | $490.42 Million | +14.55pp |
| 2022-12-31 | 61.82% | $268.97 Million | $435.09 Million | -14.11pp |
| 2021-12-31 | 75.92% | $154.67 Million | $203.71 Million | +13.65pp |
| 2020-12-31 | 62.28% | $81.74 Million | $131.25 Million | +55.67pp |
| 2019-12-31 | 6.61% | $2.00 Million | $30.26 Million | -38.56pp |
| 2018-12-31 | 45.16% | $29.88 Million | $66.15 Million | -- |
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develo… Read more